Jeffrey Lieberman

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 163:611-22. 2006
  2. ncbi Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia
    Jeffrey A Lieberman
    Columbia University College of Physicians and Surgeons, New York, NY, USA
    CNS Spectr 12:1-13; quiz 14. 2007
  3. ncbi Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE)
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    Arch Gen Psychiatry 63:1069-72. 2006
  4. ncbi Science and recovery in schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Psychiatr Serv 59:487-96. 2008
  5. ncbi Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection
    Jeffrey A Lieberman
    Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, 1051 Riverside Dr, Unit 4, New York, NY 10032, USA
    Pharmacol Rev 60:358-403. 2008
  6. ncbi A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Neuropsychopharmacology 34:1322-9. 2009
  7. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
  8. ncbi A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)
    T Scott Stroup
    Columbia University College of Physicians and Surgeons, New York, USA
    Am J Psychiatry 168:947-56. 2011
  9. ncbi Substance use and schizophrenia: adverse correlates in the CATIE study sample
    Karin E Kerfoot
    Department of Psychiatry, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
    Schizophr Res 132:177-82. 2011
  10. ncbi The association between weight change and symptom reduction in the CATIE schizophrenia trial
    Eric Hermes
    Department of Psychiatry, Yale School of Medicine, 300 George Street, Ste 901, New Haven, CT 06511, USA
    Schizophr Res 128:166-70. 2011

Research Grants

  1. BRAIN MRI & MRS CHANGES IN FIRST EPISODE SCHIZOPHRENIA
    Jeffrey Lieberman; Fiscal Year: 2004
  2. PAR04-122 Satellite Animal Facility Construction Project
    Jeffrey Lieberman; Fiscal Year: 2009
  3. Pharmacologic and Clinical Testing of a D1 Agonist for Neuropsychiatric Disorders
    Jeffrey Lieberman; Fiscal Year: 2005

Detail Information

Publications71

  1. ncbi Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic
    T Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Am J Psychiatry 163:611-22. 2006
    ..This randomized, double-blind study compared olanzapine, quetiapine, risperidone, and ziprasidone in patients who had just discontinued a different atypical antipsychotic...
  2. ncbi Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia
    Jeffrey A Lieberman
    Columbia University College of Physicians and Surgeons, New York, NY, USA
    CNS Spectr 12:1-13; quiz 14. 2007
    ..Finally, L. Fredrik Jarskog, MD, focuses on the neurobiology of functional progression in schizophrenia as well as pharmacology and the potential for neuroprotection...
  3. ncbi Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE)
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    Arch Gen Psychiatry 63:1069-72. 2006
  4. ncbi Science and recovery in schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Psychiatr Serv 59:487-96. 2008
    ..Future clinical and neuroscience research and service development should emphasize measures of recovery as outcomes for people with schizophrenia...
  5. ncbi Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection
    Jeffrey A Lieberman
    Department of Psychiatry, Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute, 1051 Riverside Dr, Unit 4, New York, NY 10032, USA
    Pharmacol Rev 60:358-403. 2008
    ....
  6. ncbi A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Neuropsychopharmacology 34:1322-9. 2009
    ..6 and 3.0% of patients in these groups, respectively. Memantine showed no efficacy as an adjunctive therapy in schizophrenia patients with residual psychopathology and was associated with a higher incidence of AEs than placebo...
  7. ncbi Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Jeffrey A Lieberman
    Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York State Psychiatric Institute, New York, NY 10032, USA
    N Engl J Med 353:1209-23. 2005
    ..We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study...
  8. ncbi A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)
    T Scott Stroup
    Columbia University College of Physicians and Surgeons, New York, USA
    Am J Psychiatry 168:947-56. 2011
    ..The authors conducted a multisite randomized controlled trial examining the strategy of switching from olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate metabolic risk factors for cardiovascular disease...
  9. ncbi Substance use and schizophrenia: adverse correlates in the CATIE study sample
    Karin E Kerfoot
    Department of Psychiatry, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06510, USA
    Schizophr Res 132:177-82. 2011
    ....
  10. ncbi The association between weight change and symptom reduction in the CATIE schizophrenia trial
    Eric Hermes
    Department of Psychiatry, Yale School of Medicine, 300 George Street, Ste 901, New Haven, CT 06511, USA
    Schizophr Res 128:166-70. 2011
    ..Weight gain and changes in metabolic indicators associated with some antipsychotics may be related to symptom improvement and thus an unavoidable correlate of clinical benefit...
  11. ncbi Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial
    Scott Stroup
    Department of Psychiatry, University of North Carolina at Chapel Hill, CB 7160, Chapel Hill, NC 27599 7160, USA
    Schizophr Res 80:1-8. 2005
    ....
  12. ncbi AKT1 and neurocognition in schizophrenia
    Andrea Poyastro Pinheiro
    Department of Psychiatry, University of North Carolina at Chapel Hill, NC, USA
    Aust N Z J Psychiatry 41:169-77. 2007
    ..Therefore, the association of genetic variation in AKT1 with neurocognition was investigated in patients with schizophrenia...
  13. ncbi Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression
    Jie Huang
    Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research, and Psychiatric Genetics Program in Mood and Anxiety Disorders, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
    Am J Psychiatry 167:1254-63. 2010
    ..The purpose of this study was to apply genomewide association study (GWAS) analysis to address the specificity of genetic effects on these disorders...
  14. ncbi Brain volumes in psychotic youth with schizophrenia and mood disorders
    Mohamed El-Sayed
    Department of Psychiatry, University of North Carolina at Chapel Hill, NC 27599 7160, USA
    J Psychiatry Neurosci 35:229-36. 2010
    ..We sought to test the hypothesis that deficits in grey matter volume are characteristic of psychotic youth with early-onset schizophrenia-spectrum disorders (EOSS) but not of psychotic youth with early-onset mood disorders (EOMD)...
  15. ncbi Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:428-36. 2007
    ..This study examined the relative effects of the second-generation antipsychotic drugs and an older representative agent on psychosocial functioning in patients with chronic schizophrenia...
  16. ncbi Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study
    T Scott Stroup
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC
    Am J Psychiatry 164:415-27. 2007
    ..This randomized, double-blind study compared olanzapine, quetiapine, and risperidone in patients who had just discontinued the older antipsychotic perphenazine...
  17. ncbi Effectiveness of switching antipsychotic medications
    Susan M Essock
    Department of Psychiatry, Division of Health Services Research, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Am J Psychiatry 163:2090-5. 2006
    ....
  18. ncbi Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study
    Kate X Zhong
    AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, USA
    J Clin Psychiatry 67:1093-103. 2006
    ..Somnolence was more common with quetiapine; EPS and elevated prolactin rates were significantly higher with risperidone...
  19. ncbi Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease
    Lon S Schneider
    Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    N Engl J Med 355:1525-38. 2006
    ..We assessed the effectiveness of atypical antipsychotic drugs in outpatients with Alzheimer's disease...
  20. ncbi Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment
    Joseph P McEvoy
    Clinical Research Service, John Umstead Hospital, 1003 12th St, Bldg 32, Butner, NC 27705, USA
    Am J Psychiatry 163:600-10. 2006
    ....
  21. ncbi Insight in first-episode psychosis
    Joseph P McEvoy
    John Umstead Hospital, Duke University Department of Psychiatry, Butner, NC 27509, USA
    Psychol Med 36:1385-93. 2006
    ....
  22. ncbi The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham NC 27710, United States
    Schizophr Res 100:39-52. 2008
    ..This double-blind study compared a second generation (atypical) antipsychotic drugs compared to a representative older agent for patients with schizophrenia who use or avoid illicit substances...
  23. ncbi Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
    ..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined...
  24. ncbi Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study
    Linmarie Sikich
    University of North Carolina at Chapel Hill, NC 27514, USA
    Am J Psychiatry 165:1420-31. 2008
    ....
  25. ncbi Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia
    Jeffrey W Swanson
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, 905 West Main Street, Durham, NC 27710, USA
    Br J Psychiatry 193:37-43. 2008
    ..Violence is an uncommon but significant problem associated with schizophrenia...
  26. ncbi Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study
    Bruce J Kinon
    Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 28:392-400. 2008
    ....
  27. ncbi Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, San Diego, CA 92161, United States
    Schizophr Res 103:104-9. 2008
    ..Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial...
  28. ncbi Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial
    David L Sultzer
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Am J Psychiatry 165:844-54. 2008
    ..The study measured the effects of atypical antipsychotics on psychiatric and behavioral symptoms in patients with Alzheimer's disease and psychosis or agitated behavior...
  29. ncbi What CATIE found: results from the schizophrenia trial
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Psychiatr Serv 59:500-6. 2008
    ..Patient characteristics and clinical circumstances affected drug effectiveness; these patient factors are important in making treatment choices...
  30. ncbi Relationship of cognition and psychopathology to functional impairment in schizophrenia
    Somaia Mohamed
    New England Mental Illness, Research, Education and Clinical Center, Department of Veterans Affairs, West Haven, Conn 06516, USA
    Am J Psychiatry 165:978-87. 2008
    ..This study evaluated the association of neurocognition and symptoms with measures of social and occupational functioning in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)...
  31. ncbi Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study
    Diana O Perkins
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, USA
    J Clin Psychiatry 69:106-13. 2008
    ..To evaluate predictors of treatment discontinuation against medical advice and poor medication adherence among first-episode patients treated with olanzapine, quetiapine, or risperidone...
  32. ncbi Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics
    Jean A Frazier
    Cambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA
    J Am Acad Child Adolesc Psychiatry 46:979-88. 2007
    ..We examined baseline demographic and clinical profiles of youths enrolled from 2001 to 2006 in the publicly funded multicenter, randomized controlled trial Treatment of Early-Onset Schizophrenia Spectrum Disorders...
  33. ncbi Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods
    Jon McClellan
    University of Washington, Seattle, USA
    J Am Acad Child Adolesc Psychiatry 46:969-78. 2007
    ..The rationale, design, and methods of the Treatment of Early Onset Schizophrenia Spectrum Disorders Study are described...
  34. ncbi Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Am J Psychiatry 164:1061-71. 2007
    ..The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis...
  35. ncbi Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison
    Joseph P McEvoy
    Duke University Medical Center, Durham, NC, USA
    Am J Psychiatry 164:1050-60. 2007
    ....
  36. ncbi Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study
    Marvin S Swartz
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    J Nerv Ment Dis 194:164-72. 2006
    ....
  37. ncbi Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode
    Diana O Perkins
    Department of Psychiatry, C.B.# 7160, University of North Carolina School of Medicine, Chapel Hill, 27599-7160, USA
    Schizophr Res 83:53-63. 2006
    ....
  38. ncbi Myocarditis during clozapine treatment
    David B Merrill
    Department of Psychiatry, New York State Psychiatric Institute, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA. [corrected
    Am J Psychiatry 163:204-8. 2006
  39. ncbi First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol
    Alan I Green
    Commonwealth Research Center and the Massachusetts Mental Health Center, Harvard Medical School, 74 Fenwood Road, Boston, MA 02115, USA
    Schizophr Res 66:125-35. 2004
    ..We report on rates of co-occurring substance use disorders in patients within their first episode of schizophrenia-related psychosis from a multicenter, international treatment trial of olanzapine vs. haloperidol...
  40. ncbi Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan Kline Institute, Orangeburg, NY 10982, USA
    J Clin Psychiatry 65:57-61. 2004
    ....
  41. ncbi A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial
    Linmarie Sikich
    Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7160, USA
    Neuropsychopharmacology 29:133-45. 2004
    ..However, youth treated with risperidone and olanzapine experienced weight gain and extrapyramidal effects that appear more prevalent and severe than reported in adults...
  42. ncbi Schizophrenia, VI: Treatments
    Jeffrey A Lieberman
    UT Southwestern Medical Center, Department of Psychiatry, Dallas TX 75390-9070, USA
    Am J Psychiatry 160:1748. 2003
  43. ncbi Clozapine as a first treatment for schizophrenia
    Margaret G Woerner
    Department of Psychiatry, Zucker Hillside Hospital of the North Shore Long Island Jewish Health System, Glen Oaks, NY 11004, USA
    Am J Psychiatry 160:1514-6. 2003
    ..The authors' goal was to explore whether clozapine given as the first antipsychotic treatment favorably affects the course of schizophrenia...
  44. ncbi Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol
    Jeffrey A Lieberman
    Department of Psychiatry, University of North Carolina School of Medicine, NC 27599 7160, USA
    Am J Psychiatry 160:1396-404. 2003
    ..This study compared the acute and long-term effectiveness of haloperidol with that of olanzapine in patients with first-episode psychosis in a large, controlled clinical trial...
  45. ncbi Impairments in perceptual competency and maintenance on a visual delayed match-to-sample test in first-episode schizophrenia
    Todd Lencz
    Department of Psychiatry, The Zucker Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, NY, USA
    Arch Gen Psychiatry 60:238-43. 2003
    ..It was hypothesized that patients in the first episode of schizophrenia would exhibit dissociable deficits in both WM domains...
  46. ncbi Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics
    Jean Pierre Lindenmayer
    Nathan Kline Institute fo Psychiatric Research, New York, NY 10035, USA
    Am J Psychiatry 160:290-6. 2003
    ....
  47. ncbi Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents
    Christine E Marx
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina 27705, USA
    Neuropsychopharmacology 28:1-13. 2003
    ..Alterations in this neuroactive steroid may result in the modulation of GABAergic and dopaminergic neurotransmission, potentially contributing to antipsychotic efficacy...
  48. ncbi Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study
    Jean Pierre Lindenmayer
    Psychopharmacology Research Unit, Manhattan Psychiatric Center, Wards Island, NY 10035, USA
    J Clin Psychiatry 63:931-5. 2002
    ....
  49. ncbi Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder
    Delbert G Robinson
    Department of Psychiatry Research, Hillside Hospital, North Shore Long Island Jewish Health System, Glen Oaks, New York 11004, USA
    Schizophr Res 57:209-19. 2002
    ..Although extensively studied in multi-episode patients, little data exist on medication adherence by first-episode patients...
  50. ncbi Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs
    Candace Andersson
    Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599, USA
    Neuropsychopharmacology 27:143-51. 2002
    ..The current data suggests that such differential responses may be due to both the pharmacological properties and the relative doses of the atypical agents...
  51. ncbi Neurocognitive correlates of response to treatment in formal thought disorder in patients with first-episode schizophrenia
    Rita Z Goldstein
    Brookhaven National Laboratory, Upton, New York 11973, USA
    Neuropsychiatry Neuropsychol Behav Neurol 15:88-98. 2002
    ..To examine the independent contribution of executive versus semantic function to improvement in formal thought disorder after initial stabilization in a first-episode sample...
  52. ncbi Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
    Robert M Bilder
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Am J Psychiatry 159:1018-28. 2002
    ....
  53. ncbi Antipsychotic-induced weight gain and therapeutic response: a differential association
    Pal Czobor
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, New York 10962, USA
    J Clin Psychopharmacol 22:244-51. 2002
    ..These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain...
  54. ncbi COMT158 polymorphism and hostility
    Jan Volavka
    Nathan Kline Institute, Orangeburg, New York 10982, USA
    Am J Med Genet B Neuropsychiatr Genet 127:28-9. 2004
    ..The Met-Met homozygotes (N = 7) were found to have significantly higher levels of hostility than the other patients (N = 53). The hypothesis was thus supported. The finding should be replicated in a larger sample...
  55. ncbi Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia
    Jean Pierre Lindenmayer
    Nathan Kline Institute, Orangeburg, N Y, USA
    J Clin Psychiatry 65:551-6. 2004
    ..We are exploring whether this expanded clinical efficacy can also be seen in patients with treatment-resistant schizophrenia...
  56. ncbi Olanzapine versus risperidone in newly admitted acutely ill psychotic patients
    John E Kraus
    Adult Admissions Psychiatry, Dorothea Dix Hospital, 3601 Mail Service Center, Raleigh, N C 27699 3601, USA
    J Clin Psychiatry 66:1564-8. 2005
    ..This outcome was selected as it is an indirect measure of how well patients are responding to the medication and represents a "real world" endpoint relevant to practicing hospital psychiatrists...
  57. ncbi Interpreting the results of the CATIE study
    Jeffrey A Lieberman
    Psychiatr Serv 57:139. 2006
  58. ncbi From clinical research to clinical practice: a 4-year review of ziprasidone
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA
    CNS Spectr 10:1-20. 2005
    ..This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania...
  59. ncbi Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
    Robert B Zipursky
    Schizophrenia Programme, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8
    Br J Psychiatry 187:537-43. 2005
    ..Substantial weight gain is common with many atypical antipsychotics...
  60. ncbi Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder
    Matthew J Hoptman
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA
    Psychiatry Res 140:133-45. 2005
    ..Larger left OFC gray matter volumes and larger OFC white matter volumes bilaterally were associated with greater levels of aggression. These findings are discussed in the context of potential iatrogenic effects...
  61. ncbi Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA
    Biol Psychiatry 59:97-105. 2006
    ..Neurocognitive deficits are severe in first-episode psychosis...
  62. ncbi Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode
    Stephen M Strakowski
    Center for Imaging Research and Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, 231 Albert Sabin Way ML0583, Cincinnati, OH 45267 0583, USA
    Schizophr Res 78:161-9. 2005
    ..This improvement is particularly relevant early in the course of schizophrenia...
  63. ncbi Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation
    Jan Volavka
    Schizophr Res 76:127-9. 2005
  64. ncbi The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia
    Daniel J Muller
    Neurogenetics Section, Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, 250 College Street R30, Toronto, Ont M5T 1R8, Canada
    Neurosci Lett 379:81-9. 2005
    ..Weight changes do not seem to be associated with polymorphism of the SNAP-25 gene, however, replication in independent samples is warranted...
  65. ncbi Antipsychotic drug effects on brain morphology in first-episode psychosis
    Jeffrey A Lieberman
    Departments of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Arch Gen Psychiatry 62:361-70. 2005
    ..This raises the possibility that antipsychotics might alter such pathomorphologic progression in early-stage schizophrenia...
  66. ncbi Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder
    Karen A Nolan
    Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA
    J Psychiatr Res 39:109-15. 2005
    ..These findings in chronic, treatment resistant inpatients support the view that positive symptoms may lead to aggression...
  67. ncbi Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
    ..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings...
  68. ncbi Premorbid functioning in schizophrenia: relation to baseline symptoms, treatment response, and medication side effects
    Rael D Strous
    Chronic Impatient Department, Beer Yaakov Mental Health Center, Tel Aviv University, Tel Aviv, Israel
    Schizophr Bull 30:265-78. 2004
    ..Measures of premorbid functioning indicate that disease pathogenesis is manifest, albeit more subtly, prior to presentation of first psychotic symptoms...
  69. ncbi Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    J Clin Psychopharmacol 24:225-8. 2004
    ..Clozapine appears to have superior antiaggresive effects in treatment-resistant patients; this superiority develops after the patient has been exposed to an adequate dose regimen...
  70. ncbi Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, USA
    Am J Psychiatry 161:985-95. 2004
    ..This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis...
  71. ncbi Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder
    Jan Volavka
    Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY 10982, USA
    Am J Psychiatry 159:255-62. 2002
    ....

Research Grants7

  1. BRAIN MRI & MRS CHANGES IN FIRST EPISODE SCHIZOPHRENIA
    Jeffrey Lieberman; Fiscal Year: 2004
    ..This study will provide important information about the clinical and neuropathological course of subgroups of schizophrenia and therapeutic strategies for early identification and intervention. ..
  2. PAR04-122 Satellite Animal Facility Construction Project
    Jeffrey Lieberman; Fiscal Year: 2009
    ..The design will meet all NIH guidelines for the care and use of laboratory animals and health and safety regulations for staff. ..
  3. Pharmacologic and Clinical Testing of a D1 Agonist for Neuropsychiatric Disorders
    Jeffrey Lieberman; Fiscal Year: 2005
    ....